Finally, we identify LPAR1 as a therapeutic target on collagen-producing CaHSCs, demonstrating that blockade of LPAR1 inhibits liver fibrosis in a rodent NASH model. This evidence concerns the gene LPAR1 and metabolic dysfunction-associated steatohepatitis.